Supporting Information


Phenolics from Phaleria nisidai with Estrogenic Activity

Christopher Kitalong$^{1,2}$, El-Halawany Ali M.$^{2,3,*}$, Riham salah El-Dine, Chao-mei Ma$^2$, Masao Hattori$^2$

$^1$The Graduate Center, City University of New York, Lehman College Campus Bronx, NY, USA
$^2$Institute of Natural Medicine, University of Toyama; 2630 Sugitani, Toyama 930-0194, Japan,
$^3$Faculty of Pharmacy, Department of Pharmacognosy, Cairo University, Kasr El-Aini St. 11562, Cairo, Egypt.

Content                                                                                                               page

$^1$H and $^{13}$C NMR charts of isolated compounds 1 and 2                                  2

Experimental part                                                              6

Extraction and isolation of compounds                                               6

Ligand binding assay                                                             7

Virtual docking                                                                  8

1

1
$^1$H-$^1$H COSY of compound 1

HMOC of compound 1
HMBC of compound 1

$^1$H-NMR of compound 2
$^{13}$C-NMR of compound 2

HMOC of compound 2
Experimental

General Experimental Procedures

$^1$H- and $^{13}$C-NMR were measured with a JHA-LAA 400 WB-FT ($^1$H, 400 MHz; $^{13}$C, 100 MHz; Jeol Co., Tokyo) spectrometer, the chemical shifts being represented as ppm with tetramethylsilane as an internal standard. ESI-MS was carried out on an Esquire 3000 mass spectrometer (Bruker Daltanik GmbH, Bremen, Germany) system with an ESI ionization source. TLC was carried out on pre-coated silica gel 60 F$_{254}$ (0.25 mm, Merck) and RP-18 F$_{254}$S (0.25 mm, Merck Co., Darmstadt). Column chromatography (CC) was carried out on BW-820MH silica gel, Diaion HP-20 (Mitsubishi Kasei, Tokyo) and Sephadex LH-20 (Pharmacia Co.), Wakosil C-300 silica gel (40-63 µm) (Wako Chem. Co., Osaka, Japan) and ODS DM 1020T (ODS, Fuji Sylisia, Nagoya, Japan). Medium pressure liquid chromatography (MPLC) was performed on LiChroprep RP-18 and LiChroprep Si 60 (size A and B, Merck Co.).

Extraction and isolation

_P. nisidai_ dried leaves (500 g) were extracted with methanol, under reflux, for three hours, three times and dried under reduced pressure. The crude extract (53g) was then suspended in distilled water and extracted with chloroform (3 X 250ml) to yield a chloroform fraction (4 gm). The water-
soluble fraction afforded a precipitate upon concentration. The precipitate was washed repeatedly with chloroform, and subsequently washed repeatedly with methanol to obtain compound 3 (13 g). The remaining water layer was subsequently run over Diaion HP20 column (5X60 cm) yielding three fractions: H2O, 50% MeOH and 100% MeOH.

The 50% MeOH fraction (7 g) was subjected to ODS column (2X20 cm), eluted with MeOH:H2O 1:9 v/v increasing methanol gradiently till 80%, and 9 fractions were collected. Fraction 3 (900 mg) was dried and washed with MeOH to afford mangiferin crystals. The supernatant of fraction 3 was run over ODS column (1X15 cm), eluted with MeOH: H2O gradiently (10% ~ 50%). Four fractions were collected: 3a-3d. Fraction 3d was then run over MPLC on a RP-18 size A column, using MeOH:H2O (6:4 v/v) to afford compound 2 (237.2 mg). Fraction 7 (500 mg) was applied to MPLC column (RP-18, size A) and eluted with MeOH:H2O (7:3 v/v) to obtain compound 1 (20 mg).

**Acid hydrolysis of compound 1 and 2**

A solution of 1 and 2 (4 mg of each) in a 1% H2SO4 (0.2 ml) in a sealed tube was heated on a boiling water bath for 1h[1, 2]. The solution was then extracted with EtOAc and concentrated under vacuum to get compounds 4 and 5, respectively. The identity of the aglycones was verified by comparison with the reported data[3].

**Estrogenic activity**

*Ligand binding assay*

An estrogen receptor (α) competitor assay kit (Wako Chemical Japan Inc.) was employed to determine the efficacy of test compounds to bind to the estrogen receptor (ERα). Direct comparisons were performed with a labeled estrogen mixture. The amount of the ligand that binds to the ERα coated on the microplate well was determined by a dynamic equilibrium among all the ligand concentrations in the mixture, the difference of their binding affinities to the receptor, and incubation time. A reduction in fluorescence intensities from the labeled estrogens provides a measure of the affinity of the added compounds to the estrogen receptor. The prepared derivatives were tested at concentrations of 10^{-5}, 10^{-4} and 10^{-3} M. 17-β estradiol (E2) was used as a positive control. The assay was carried out according to the method reported by the company, briefly; the test compounds were prepared as stock in DMSO. 6 µl of each dilution was added to labeled estrogen mixture (114 µl) and mixed well in a micro tube. 100 µl of the prepared mixture is pipetted into each well in the supplied ERα coated microplate. DMSO (5% in the estrogen labeled mixture) was used as the control. The
plate is incubated at room temperature for exactly 2 h. The microplate was washed with 100 ml of the wash solution followed by draining the residual solutions from the wells. 100 µl of the assay solution was added to every well and the fluorescence intensity in each well was measured at excitation 485 nm and emission 535 nm. The results were calculated as percentages of the control. The fluorimetric analyses were performed on an automated TECAN GENios plate reader with excitation wavelength at 485 nm and emission at 530 nm. Results were calculated as percentages of labeled estrogen mixture binding.

**Virtual Docking Study**

The crystal structure of estrogen receptor α (ERα) bound to 17β estradiol (protein data bank ID 1A52) was downloaded from [www.pdb.org](http://www.pdb.org). The crystal structure was prepared for docking study using the Internal Coordinate Mechanics (ICM-Pro) software version 3.4-8C (MolSoft LLC, San Diego CA) [4]. The crystal structure was first transformed to ICM object and the water molecules were eliminated. The protein model was adjusted (regularized) so that the optimal positions of polar hydrogens were identified, missing hydrogen and heavy atoms were added, atom types and partial charges were assigned. The 3D structures of the ligand molecules were generated and energy minimized using Merck Molecular Force Field (MMFF). The active site of the regularized protein was identified and adjusted using the ICM small molecule docking procedure (MolSoft ICM manual). Receptor energy maps were constructed including energy terms for electrostatic, directional hydrogen bond, hydrophobic interactions, and two van der Waals interactions for steric repulsion and dispersion attraction. Finally, docking was carried out using interactive docking using one ligand at a time (interactive docking/Mol table ligand) and the ICM scores were calculated. Re-docking of the co-crystal structure ligand (17β estradiol) and calculating the RMSD were carried out; the results were compared to the literature to validate the docking process.

**Statistical analysis**

The IC₅₀ was calculated using a non-linear regression analysis (for one site competition). Data was represented as means±S.E.M.

**References**

